SEC Company Response from Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320) (ADPT) — Jan 21, 2020
Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320)
Date: Jan. 21, 2020 · CIK: 0001478320 · Accession: 0001193125-20-011129
AI Filing Summary & Sentiment
File numbers found in text: 333-235989
Letter
Re: Adaptive Biotechnologies Corporation
January 21, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Registration Statement on Form S-1
File No. 333-235989
Acceleration Request
Requested Date: January 23, 2020
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Adaptive Biotechnologies Corporation hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:30 p.m., Eastern Time, on January 23, 2020, or as soon thereafter as practicable.
Please confirm once the Registration Statement has been declared effective by calling Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845. Please also contact him should you have any questions.
Very truly yours,
Adaptive Biotechnologies Corporation
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
January 21, 2020
VIA EDGAR
U.S. Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, D.C. 20549
Attention:
Tim Buchmiller
Re:
Adaptive Biotechnologies Corporation
Registration Statement on Form S-1
File No. 333-235989
Acceleration Request
Requested Date: January 23, 2020
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Adaptive Biotechnologies Corporation hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:30 p.m., Eastern Time, on January 23, 2020, or
as soon thereafter as practicable.
Please confirm once the Registration Statement has been declared effective by calling Andrew Ledbetter of DLA Piper
LLP (US) at (206) 839-4845. Please also contact him should you have any questions.
Very truly yours,
Adaptive Biotechnologies Corporation
/s/ Chad Robins
Chad Robins
Chief Executive Officer
cc:
Chad Cohen, Chief Financial Officer
Stacy Taylor, General Counsel
Adaptive Biotechnologies Corporation
Andrew Ledbetter, Esq.
Tyler
Hollenbeck, Esq.
DLA Piper LLP (US)
James Evans, Esq.
Amanda Rose,
Esq.
Jennifer Hitchcock, Esq.
Fenwick & West LLP